INSILICO(03696.HK) closed 14.06% higher,The full-day turnover stood at HKD 618.6 million
NewTimeSpace News: By the close of trading on Apr 20, 2026, INSILICO(03696.HK) saw a gain of 14.06% in its share price, closing at HKD 69.35. During the session, it reached an intraday high of HKD 71.7 and touched an intraday low of HKD 60.4. The full-day turnover stood at HKD 618.6 million, with significant volume growth, with the latest market capitalization at HKD 39.7 billion.
On the sector front, the Hang Seng Pharmaceuticals & Biotechnology Sector, to which INSILICO belongs, showed an overall divergence trend, with 60 stocks advancing and 76 stocks declining.Among the gainers, INSILICO closed higher by 14.06%, KONTA CHINA closed higher by 6.9%, CIRC closed higher by 6.85%, CARSGEN-B closed higher by 6.75%, 3D MEDICINES closed higher by 6.4%.Among the decliners, SIPAI HEALTH closed lower by 8.7%, BIOSTAR PHARM-B closed lower by 8.25%, PASHUN INT'L closed lower by 7.69%, SIMCERE PHARMA closed lower by 7.32%, XUANZHUBIO-B closed lower by 7.21%.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- InSilico Medicine (03696.HK): NLRP3 Inhibitor ISM8969/HT-001 Co-Developed with Hengtai Bio Receives NMPA IND Approval for Parkinson's Disease
- Empowered by HKIC's Patient Capital, Insilico Medicine (3696.HK) Enters $600 Million Global Strategic Partnership with Takeda
- InSilico Medicine (03696.HK) and Bora Pharmaceuticals Announce Strategic Alliance with Potential Value Exceeding US$2.5 Billion
- INSILICO (03696.HK): Enters CNS Drug R&D Collaboration with Cosmo Pharmaceutical, Potential Milestone Payments Up to Approximately RMB1.2 Billion
- InSilico Medicine (03696.HK): Expects to Turn Profit in H1, Net Profit of US$33.5M to US$39.5M